SNDX Syndax Pharmaceuticals Inc.

5.11
-0.07  -1%
Previous Close 5.18
Open 5.23
Price To Book 2.41
Market Cap 127753781
Shares 25,000,740
Volume 162,739
Short Ratio
Av. Daily Volume 139,903

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 603
Ovarian cancer
Phase 2 top-line data March 7, 2019 failed to meet endpoints.
Entinostat plus Tecentriq - ENCORE 602
Triple negative breast cancer (TNBC)
Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.
Entinostat plus Keytruda - ENCORE 601
Recurrent non-small cell lung cancer (NSCLC), colorectal cancer
Phase 3 PFS date did not meet primary endpoint - October 25, 2018. OS data due 2Q 2019.
E2112
HR+, HER2- breast cancer
Phase 1 poster at ASCO June 2018.
Entinostat
Solid tumors
Phase 1 initial data due 2H 2019.
SNDX-6352
Chronic graft versus host disease
Phase 1b/2 trial to be initiated 2Q 2019.
Entinostat plus NKTR-214 - ENCORE 606
Melanoma

Latest News

  1. Edited Transcript of SNDX earnings conference call or presentation 7-Mar-19 9:30pm GMT
  2. What Do Analysts Think About Syndax Pharmaceuticals, Inc.’s (NASDAQ:SNDX) Earnings Trend?
  3. Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update
  4. Syndax to Present at the Cowen 39th Annual Health Care Conference
  5. Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019
  6. Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019
  7. Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
  8. New Research: Key Drivers of Growth for Cronos Group, Spectrum Brands, Black Hills, Entercom Communications, CSS Industries, and Syndax Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  9. Syndax Highlights 2019 Clinical and Corporate Outlook
  10. Can We See Significant Institutional Ownership On The Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Share Register?
  11. Edited Transcript of SNDX earnings conference call or presentation 5-Nov-18 9:30pm GMT
  12. Syndax Pharmaceuticals Announces Presentation of Preclinical Data from Menin-MLL Program at the 60th American Society of Hematology Annual Meeting
  13. Investor Expectations to Drive Momentum within CommScope Holding, AMC Networks, Henry Schein, Lindblad Expeditions, Apple Hospitality REIT, and Syndax Pharmaceuticals — Discovering Underlying Factors of Influence
  14. Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Lags Revenue Estimates
  15. Syndax Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Clinical and Business Update
  16. Syndax Pharmaceuticals Announces Presentations at the 60th American Society of Hematology Annual Meeting
  17. Syndax to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 5, 2018
  18. The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default
  19. Syndax to Host Conference Call to Provide Update on the Phase 3 Breast Cancer Trial (E2112) and to Announce its Registration Trial of Entinostat with Keytruda in PD-(L)1 Refractory Non-Small Cell Lung Cancer